ONCOMECHAML SIGNED
Common Oncogenic Mechanisms in Multi-Partner Translocation Families in Acute Myeloid Leukemia
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0ONCOMECHAML project word cloud
Explore the words cloud of the ONCOMECHAML project. It provides you a very rough idea of what is the project "ONCOMECHAML" about.
Project "ONCOMECHAML" data sheet
The following table provides information about the project.
| Coordinator |
VETERINAERMEDIZINISCHE UNIVERSITAET WIEN
Organization address contact info |
| Coordinator Country | Austria [AT] |
| Total cost | 1˙499˙500 € |
| EC max contribution | 1˙499˙500 € (100%) |
| Programme |
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC)) |
| Code Call | ERC-2014-STG |
| Funding Scheme | ERC-STG |
| Starting year | 2015 |
| Duration (year-month-day) | from 2015-06-01 to 2020-05-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | VETERINAERMEDIZINISCHE UNIVERSITAET WIEN | AT (VIENNA) | coordinator | 513˙990.00 |
| 2 | LUDWIG BOLTZMANN GESELLSCHAFT GMBH | AT (WIEN) | participant | 985˙509.00 |
Map
Project objective
Acute Myeloid Leukemia (AML) is the most frequent cancer of the blood system, with >80% mortality within 5 years of diagnosis. Straightforward clinical decisions are complicated by the genetic complexity of AML. In particular, fusion proteins arising from chromosomal aberrations are recurrently found in AML and often act as strong driver oncogenes. In “Multi-Partner Translocation” (MPT) families, one specific gene is fused to many recipient loci. Due to this modular architecture, MPT families are of particular interest to comparative studies of oncogenic mechanisms. The three most common MPT families in AML represent translocations of the MLL, RUNX1 and NUP98 genes. Despite their clinical significance, the molecular mechanism of transformation remains unknown for the majority of fusion proteins and it is unclear if transforming mechanisms are conserved within and across different MPT families. We hypothesize that common oncogenic mechanisms of fusion proteins are encoded in physical and genetic cellular interaction networks that are specific to MPT families. We propose to delineate critical common effectors of oncogenic mechanisms in AML driven by MPT families through a comprehensive, comparative, functional analysis of 20 clinically representative MLL-, RUNX1- and NUP98-fusion proteins using a unique experimental pipeline. Characterization of protein interactomes and their effects on gene expression will identify common cellular denominators of MPT families, whose functional contribution will be assessed through pooled shRNA screens in clinically relevant model systems. High-confidence hits will be validated in mouse models and primary cells from AML patients. This project will generate large informative datasets and novel experimental systems that are of relevance for basic and clinical cancer research. It will contribute to improved understanding of oncogenic mechanisms, which may directly impact on diagnostic and therapeutic strategies in the management of AML.
Publications
| year | authors and title | journal | last update |
|---|---|---|---|
| 2016 |
Thomas Eder, Florian Grebien, Thomas Rattei NVT: a fast and simple tool for the assessment of RNA-seq normalization strategies published pages: btw521, ISSN: 1367-4803, DOI: 10.1093/bioinformatics/btw521 |
Bioinformatics | 2019-05-27 |
| 2017 |
Katrin Noack, Nisintha Mahendrarajah, Dorle Hennig, Luisa Schmidt, Florian Grebien, Dagmar Hildebrand, Markus Christmann, Bernd Kaina, Andreas Sellmer, Siavosh Mahboobi, Katharina Kubatzky, Thorsten Heinzel, Oliver H. Krämer Analysis of the interplay between all-trans retinoic acid and histone deacetylase inhibitors in leukemic cells published pages: 2191-2208, ISSN: 0340-5761, DOI: 10.1007/s00204-016-1878-5 |
Archives of Toxicology 91/5 | 2019-05-27 |
| 2016 |
Tahereh Javaheri, Zahra Kazemi, Jan Pencik, Ha TT Pham, Maximilian Kauer, Rahil Noorizadeh, Barbara Sax, Harini Nivarthi, Michaela Schlederer, Barbara Maurer, Maximillian Hofbauer, Dave NT Aryee, Marc Wiedner, Eleni M Tomazou, Malcolm Logan, Christine Hartmann, Jan P Tuckermann, Lukas Kenner, Mario Mikula, Helmut Dolznig, Aykut Üren, Günther H Richter, Florian Grebien, Heinrich Kovar, Richard Moriggl Increased survival and cell cycle progression pathways are required for EWS/FLI1-induced malignant transformation published pages: e2419, ISSN: 2041-4889, DOI: 10.1038/cddis.2016.268 |
Cell Death and Disease 7/10 | 2019-05-27 |
| 2016 |
Jan Pencik, Ha Thi Thanh Pham, Johannes Schmoellerl, Tahereh Javaheri, Michaela Schlederer, Zoran Culig, Olaf Merkel, Richard Moriggl, Florian Grebien, Lukas Kenner JAK-STAT signaling in cancer: From cytokines to non-coding genome published pages: 26-36, ISSN: 1043-4666, DOI: 10.1016/j.cyto.2016.06.017 |
Cytokine 87 | 2019-05-27 |
| 2018 |
Ha Thi Thanh Pham, Barbara Maurer, Michaela Prchal-Murphy, Reinhard Grausenburger, Eva Grundschober, Tahereh Javaheri, Harini Nivarthi, Auke Boersma, Thomas Kolbe, Mohamed Elabd, Florian Halbritter, Jan Pencik, Zahra Kazemi, Florian Grebien, Markus Hengstschläger, Lukas Kenner, Stefan Kubicek, Matthias Farlik, Christoph Bock, Peter Valent, Mathias Müller, Thomas Rülicke, Veronika Sexl, Richard Moriggl STAT5BN642H is a driver mutation for T cell neoplasia published pages: 387-401, ISSN: 0021-9738, DOI: 10.1172/JCI94509 |
Journal of Clinical Investigation 128/1 | 2019-05-27 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ONCOMECHAML" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "ONCOMECHAML" are provided by the European Opendata Portal: CORDIS opendata.